Tamoxifen Induced Corneal Opacity in Breast Cancer Patient.
- Author:
Dong Hee RYU
1
;
Hyo Yung YUN
;
Dong Kee YU
;
Eui Tai LEE
;
Young Jin SONG
Author Information
1. Department of Surgery, Chungbuk National University College of Medicine, Cheongju, Korea. yjsong@chungbuk.ac.kr
- Publication Type:Case Report
- Keywords:
Tamoxifen;
Ocular side effects;
Corneal opacity
- MeSH:
Amiodarone;
Breast Neoplasms*;
Breast*;
Cataract;
Chloroquine;
Chlorpromazine;
Corneal Opacity*;
Crystallins;
Electrooculography;
Endometrial Neoplasms;
Estrogen Receptor Modulators;
Female;
Humans;
Macular Edema;
Optic Nerve;
Optic Neuritis;
Retina;
Retinaldehyde;
Tamoxifen*;
Thromboembolism;
Vaginal Discharge
- From:Journal of the Korean Surgical Society
2006;70(5):396-398
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Since 1970's, Tamoxifen has been used as an antiestrogen agent for adjuvant hormonal therapy, targeting hormone receptor positive breast cancer. Tamoxifen has adverse side effects such as menopausal hot flush, vaginal discharge, irregular menses, thromboembolism, and uterine endometrial carcinoma. Tamoxifen has structure and side effects similar to amphiphilic cationic agents like chlorpromazine, thorazine, amiodarone, and chloroquine. With long period use in high dose, tamoxifen can cause ocular side effects such as retinal crystalline deposition, macular edema, whorl-like corneal opacities, posterior subcapsular lens opacities, optic neuritis, and affected EOG. Recently several reports showed that ocular side effect could happen even in low dose standard treatment. We experienced a case of keratopathy of corneal opacity without disorder of retina, lens, and optic nerve in low dose tamoxifen therapy for breast cancer.